ITSS,
Although you've "read the thread" etc., there's a lot of thread and etc. Here are links to a few highlights for you and anyone else who's tuned in recently:
An excellent 4/99 overview of GLIA, by NeuroInvestment: neuroinvestment.com
Rick Harmon's summary of the GLIA conference call re 1Q99 earnings: Message 9106997
Rick's summary of conference call re 2Q99 earnngs: Message 10691976
A summary (by Spyros1950) of the May 19,1999 annual meeting, at this Yahoo post and the next couple of posts: messages.yahoo.com
Summaries of last year's annual meeting (5/20/98): Message 4679870 and Message 4553245
There is a series of posts by BioFreak2 (a/k/a Rick Harmon) outlining the "top ten reasons to own GLIA" on the Yahoo GLIA board, starting at #2656: messages.yahoo.com
Also: "Not counting Adcons other than -P, the company now has at least five development programs, one of which is in pivotal human trials and one of which has completed single-dose phase I. I suspect that the H(3) news has gotten better and better, and that Oesterling is making a grab for independent pharma. Given their structure and the current mood for M&A, I see nothing but upside from this for risk-loving investors." Message 8362590 (and other discussion re pipeline).
Total U.S. surgeries annually in the six categories addressed by the Adcons were in the 5/98 S-3 excerpt posted here: Message 7671563 (these 1995 figures add up to 6,910,000 surgeries annually). In addition, GLIA announced on 6/15/99 that it is seeking to expand the use of Adcon-L to breast implant/reconstruction surgeries (300,000 annual U.S. surgeries): biz.yahoo.com
Hope this is helpful.
--RCM |
